Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (ppv23) against pneumococcal disease in the elderly: Systematic review and meta-analysis

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Falkenhorst, Gerhard ^a   Remschmidt, Cornelius ^a   Harder, Thomas ^a   Hummers Pradier, Eva ^b   Wichmann, Ole ^a   Bogdan, Christian ^c  

^a ROBERT KOCH INSTITUTE   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCAL POLYSACCHARIDE 23 VALENT VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

AGING; ARTICLE; DRUG EFFICACY; HUMAN; IMMUNITY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEROTYPE; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; VACCINATION; AGE; AGED; CLINICAL TRIAL (TOPIC); FEMALE; IMMUNOLOGY; MALE; META ANALYSIS; ODDS RATIO; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 85009151988     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169368     Document Type: Article

References (55)

1. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. European journal of clinical microbiology & infectious diseases. 2013; 32(3):305-16.
2. Klapdor B, Ewig S, Pletz MW, Rohde G, Schutte H, Schaberg T, et al. Community-acquired pneumonia in younger patients is an entity on its own. The European respiratory journal. 2012; 39(5):1156-61. doi: 10.1183/09031936.00110911 PMID: 22088967
3. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009; 6(5):e1000081. doi: 10.1371/journal.pmed.1000081 PMID: 19468297
4. Fedson DS. Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23. Hum Vaccin Immunother. 2014; 10(5):1322-30. doi: 10.4161/hv.28797 PMID: 24732438
5. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, et al. Prevention of pneumococcal pneumonia by vaccination. Transactions of the Association of American Physicians. 1976; 89:184-94. PMID: 14433
6. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977; 238(24):2613-6. PMID: 21973
7. Diao WQ, Shen N, Yu PX, Liu BB, He B. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016; 34(13):1496-503. doi: 10.1016/j.vaccine.2016.02. 023 PMID: 26899376
8. Kraicer-Melamed H, O'Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and metaanalysis. Vaccine. 2016; 34(13):1540-50. doi: 10.1016/j.vaccine.2016.02.024 PMID: 26899372
9. Kraicer-Melamed H, O'Donnell S, Quach C. Corrigendum to "The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50years of age and older: A systematic review and meta-analysis" [Vaccine 34 (2016) 1540-1550]. Vaccine. 2016; 34(34):4083-4. doi: 10. 1016/j.vaccine.2016.06.045 PMID: 27329185
10. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk-A Systematic Review and Meta-Analysis. PloS One. 2016; 11(1):e0146338. doi: 10.1371/journal.pone.0146338 PMID: 26761816
11. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. The Cochrane database of systematic reviews. 2013; 1:Cd000422.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. doi: 10.1371/journal.pmed. 1000097 PMID: 19621072
13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. doi: 10.1136/bmj. d5928 PMID: 22008217
14. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [10.07.2015]. http://www. ohri.ca/programs/clinical-epidemiology/oxford.asp.
15. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology. 2011; 64 (4):383-94. doi: 10.1016/j.jclinepi.2010.04.026 PMID: 21195583
16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration; 2011.
17. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. Journal of clinical epidemiology. 2013; 66(2):173-83. doi: 10.1016/j.jclinepi.2012.08.001 PMID: 23116689
18. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax. 2006; 61(3):189-95. doi: 10.1136/thx.2005. 043323 PMID: 16227328
19. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010; 340:c1004. doi: 10.1136/bmj. c1004 PMID: 20211953
20. Örtqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998; 351(9100):399-403. PMID: 9482293
21. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999; 17(20-21):2493-500. PMID: 10418894
22. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged >/ = 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014; 58(7):909-17. doi: 10.1093/cid/ciu002 PMID: 24532544
23. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodriguez T, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2006; 43(7):860-8. doi: 10.1086/507340 PMID: 16941367
24. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. NEJM. 2003; 348(18):1747-55. doi: 10.1056/NEJMoa022678 PMID: 12724480
25. Hechter RC, Chao C, Jacobsen SJ, Slezak JM, Quinn VP, Van Den Eeden SK, et al. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study. Vaccine. 2012; 30(38):5625-30. doi: 10.1016/j.vaccine.2012.06.085 PMID: 22789510
26. Tsai YH, Hsieh MJ, Chang CJ, Wen YW, Hu HC, Chao YN, et al. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old-Taiwan's PPV vaccination program. Vaccine. 2015; 33(25):2897-902. doi: 10.1016/j.vaccine.2015.04.068 PMID: 25936662
27. Dominguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L, Ciruela P, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis. 2005; 40 (9):1250-7. doi: 10.1086/429236 PMID: 15825026
28. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middleaged and older adults: a matched case-control study. Vaccine. 2009; 27(10):1504-10. doi: 10.1016/j. vaccine.2009.01.013 PMID: 19171174
29. Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged >/ = 65 years: a retrospective case-control study. Clin Infect Dis. 2015; 60 (10):1472-80. doi: 10.1093/cid/civ096 PMID: 25669354
30. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012; 30(48):6802-8. doi: 10.1016/j.vaccine.2012.09.019 PMID: 23000122
31. Wright LB, Hughes GJ, Chapman KE, Gorton R, Wilson D. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012. Trials in Vaccinology. 2013; 2(0):45-8.
32. Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine. 2013; 31(49):5863-71. doi: 10.1016/j.vaccine.2013.09.049 PMID: 24099873
33. Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba Deorador E, Lasheras Carbajo MD, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011. Eurosurveillance. 2014; 19 (40):20922. PMID: 25323079
34. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. NEJM. 1980; 303(10):549-52. doi: 10.1056/NEJM198009043031003 PMID: 6995835
35. Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine. 2014; 32 (19):2198-203. doi: 10.1016/j.vaccine.2014.02.048 PMID: 24613522
36. Jalonen E, Paton JC, Koskela M, Kerttula Y, Leinonen M. Measurement of antibody responses to pneumolysin-a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. The Journal of infection. 1989; 19(2):127-34. PMID: 2809235
37. Leinonen M, Syrjälä H, Jalonen E, Kujala P, Herva E. Demonstration of pneumolysin antibodies in circulating immune complexes-a new diagnostic method for pneumococcal pneumonia. Serodiagnosis and Immunotherapy in Infectious Disease. 1990; 4(6):451-8.
38. Nelson JC, Jackson ML, Weiss NS, Jackson LA. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. Journal of clinical epidemiology. 2009; 62 (7):687-94. doi: 10.1016/j.jclinepi.2008.06.014 PMID: 19124221
39. Jackson LA. Pneumococcal polysaccharide vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed: Elsevier Saunders; 2013.
40. Hollingsworth R, Isturiz R. The stubborn persistence of adult pneumococcal pneumonia as a public health problem. Hum Vaccin Immunother. 2014; 10(5):1319-21. doi: 10.4161/hv.27986 PMID: 24553362
41. Scott JA, Hall AJ, Leinonen M. Validation of immune-complex enzyme immunoassays for diagnosis of pneumococcal pneumonia among adults in Kenya. Clinical and diagnostic laboratory immunology. 2000; 7(1):64-7. PMID: 10618279
42. Musher DM, Mediwala R, Phan HM, Chen G, Baughn RE. Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis. 2001; 32(4):534-8. doi: 10.1086/318709 PMID: 11181114
43. Kaijalainen T, Saukkoriipi A, Bloigu A, Herva E, Leinonen M. Real-time pneumolysin polymerase chain reaction with melting curve analysis differentiates pneumococcus from other alpha-hemolytic streptococci. Diagn Microbiol Infect Dis. 2005; 53(4):293-9. doi: 10.1016/j.diagmicrobio.2005.07.005 PMID: 16360553
44. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/ = 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and mortality weekly report. 2014; 63(37):822-5. PMID: 25233284
45. Joint Committee on Vaccination and Immunisation (JCVI). Interim JCVI statement on adult pneumococcal vaccination in the UK. November 2015.
46. Iyer AS, Ohtola JA, Westerink MA. Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic. Expert review of vaccines. 2015; 14(1):85-97. doi: 10.1586/ 14760584.2015.963058 PMID: 25269650
47. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. NEJM. 2015; 372(12):1114-25. doi: 10.1056/ NEJMoa1408544 PMID: 25785969
48. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8):1066-73. doi: 10.1093/cid/ciu524 PMID: 25034421
49. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. The Lancet Infectious Diseases. 2015; 15(3):301-9. doi: 10.1016/S1473-3099(14)71081-3 PMID: 25656600
50. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease (IPD) among children and adults in Germany. PloS One. 2015; 10(7):e0131494. doi: 10.1371/journal.pone.0131494 PMID: 26132078
51. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. The Lancet Infectious Diseases. 2015(0).
52. Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clinical and vaccine immunology. 2012; 19(8):1131-41. doi: 10.1128/CVI.00064-12 PMID: 22675155
53. Sheppard CL, Harrison TG, Smith MD, George RC. Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific streptococcus pneumoniae antigen in urine samples. Journal of medical microbiology. 2011; 60(Pt 1):49-55. doi: 10.1099/jmm.0.023150-0 PMID: 20864547
54. Rodrigo C, Bewick T, Sheppard C, Greenwood S, McKeever TM, Trotter CL, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. The European respiratory journal. 2015; 45(6):1632-41. doi: 10.1183/09031936.00183614 PMID: 25792633
55. Pletz MW, Ewig S, Rohde G, Schuette H, Rupp J, Welte T, et al. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine. 2016; 34(20):2342-8. doi: 10.1016/j.vaccine.2016. 03.052 PMID: 27016653